Lin v. Solta Medical, Inc.

District Court, N.D. California·Decided December 23, 2024·No. 4:21-cv-05062·Unknown

Opinion

1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA

7 HSIN LIN, Case No. 21-cv-05062-PJH 8 Plaintiff,

9 v. ORDER RE PARTIES’ MOTIONS TO EXCLUDE OPINION TESTIMONY 10 SOLTA MEDICAL, INC., Re: Dkt. Nos. 112, 113, 116, 118, 119 11 Defendant. & 120 12

13 14 Before the court are (1) plaintiff’s motion to exclude expert opinion testimony of 15 Dr. Stewart Wang (Dkt. 112); (2) plaintiff’s motion to exclude expert opinion testimony of 16 Jay Bennett and Richard Malwitz (Dkt. 113); (3) defendant’s motion to exclude expert 17 opinion testimony of Monica Ip (Dkt. 116); (4) defendant’s motion to exclude expert 18 opinion testimony of Alan Schwartz (Dkt. 118); (5) defendant’s motion to exclude expert 19 opinion testimony of Dr. Christine Lee (Dkt. 119); and (6) defendant’s motion to exclude 20 expert opinion testimony of Boris Leschinsky (Dkt. 120). Although the parties filed the 21 above motions in conjunction with defendant’s motion for summary judgment, this order 22 addresses the admissibility of the challenged expert opinions for purposes of both the 23 motion for summary judgment and trial. The order granting in part and denying in part 24 defendant’s motion for summary judgment (Dkt. 155) did not rely on any of the opinions 25 excluded by this order 26 . 27 These matters are fully briefed and suitable for decision without oral argument. 1 relevant legal authority, and good cause appearing, the court hereby rules as follows. 2 DISCUSSION 3 A. Legal Standard 4 Federal Rule of Evidence 702 permits experts qualified by “knowledge, skill, 5 experience, training, or education” to testify “in the form of an opinion or otherwise” based 6 on “scientific, technical, or other specialized knowledge” if that “knowledge will help the 7 trier of fact to understand the evidence or to determine a fact in issue”. Fed. R. 8 Evid. 702. The proponent of expert testimony bears the burden of establishing by a 9 preponderance of the evidence that the admissibility requirements are met. See id., 10 Advisory Committee Notes. 11 The trial court is obliged to exercise “a gatekeeping role” regarding the admission 12 of expert scientific testimony under Rule 702. Daubert v. Merrell Dow Pharms., Inc., 509 13 U.S. 579, 597 (1993). Daubert requires a two-part analysis. First, the court must 14 determine whether an expert's testimony reflects “scientific knowledge,” whether the 15 findings are “derived by the scientific method,” and whether the work product is “good 16 science”—in other words, whether the testimony is reliable and trustworthy. Id. at 590 & 17 n.9, 593. Second, the court must determine whether the testimony is “relevant to the task 18 at hand.” Id. at 597. 19 First, scientific evidence is reliable if it is grounded in methods of science—the 20 focus is on principles and methodology, not on conclusions. Metabolife Int'l, Inc. v. 21 Wornick, 264 F.3d 832, 841 (9th Cir. 2001); see also Stilwell v. Smith & Nephew, Inc., 22 482 F.3d 1187, 1192 (9th Cir. 2007) (reliability is not determined based on the 23 “correctness of the expert's conclusions but the soundness of his methodology”). In 24 determining whether an expert's reasoning or methodology is scientifically valid, the 25 district court can consider “many factors” (Daubert, 509 U.S. at 593–94), including 26 “(1) whether the scientific theory or technique can be (and has been) tested; (2) whether 27 the theory or technique has been subjected to peer review and publication; (3) whether a 1 technique is generally accepted in the relevant scientific community.” Metabolife, 264 2 F.3d at 841. 3 Nevertheless, depending on the type of expert testimony offered, these factors 4 may not be appropriate to assess reliability. Kumho Tire Co. v. Carmichael, 526 U.S. 5 137, 152 (1999) (“the trial judge must have considerable leeway in deciding in a particular 6 case how to go about determining whether particular expert testimony is reliable”). Other 7 factors that might be considered to assess reliability include whether an expert has 8 unjustifiably extrapolated from an accepted premise to an unfounded conclusion (see 9 General Elec. Co. v. Joiner, 522 U.S. 136, 146 (1997) (“[N]othing in either Daubert or the 10 Federal Rules of Evidence requires a district court to admit opinion evidence that is 11 connected to existing data only by the ipse dixit of the expert. A court may conclude that 12 there is simply too great an analytical gap between the data and the opinion proffered.”)), 13 or whether an expert has adequately accounted for obvious alternative explanations (see 14 Claar v. Burlington Northern R. Co., 29 F.3d 499, 502 (9th Cir. 1994); Carnegie Mellon 15 Univ. v. Hoffmann–LaRoche, Inc., 55 F.Supp.2d 1024, 1034–35 (N.D. Cal. 1999) 16 (methodology may not be reliable if an expert “fail[s] to address and exclude alternative 17 explanations for the data on which he bases his findings” or “reject[s] studies reporting 18 contrary empirical findings”)). 19 The trial court should ensure the expert “employs in the courtroom the same level 20 of intellectual rigor that characterizes the practice of an expert in the relevant field.” 21 Kumho Tire, 526 U.S. at 152. The court should also consider whether an expert 22 prepared his methodology for purposes of litigation or articulated the methodology before 23 litigation and without any incentive to reach a particular outcome. See Daubert v. Merrell 24 Dow Pharms., Inc., 43 F.3d 1311, 1317 (9th Cir. 1995). 25 Second, expert testimony is relevant if the knowledge underlying it has a “valid . . . 26 connection to the pertinent inquiry.” Daubert, 509 U.S. at 591–92. As Rule 702 requires, 27 it must “help the trier of fact to understand the evidence or to determine a fact in issue.” 1 relevance] for one purpose is not necessarily scientific validity for other, unrelated 2 purposes.” Daubert, 509 U.S. at 591. 3 B. Analysis 4 1. Plaintiff’s Motion to Exclude Opinion Testimony of Dr. Stewart Wang 5 Plaintiff moves to exclude three of Dr. Wang’s four proffered opinions. 6 Specifically, she seeks to exclude the following:

7 Opinion 1. Authenticity of the Ulthera and Thermage CPT systems used during the treatment of Ms. Lin has not been 8 established.

9 Opinion 2. There is no available evidence whether the transducer (Ulthera) or the treatment tip (Thermage CPT) was 10 defective or counterfeit.

11 Opinion 3. Dr. Huang’s decision to perform off-label dual- device treatment under general anesthesia using higher than 12 moderate treatment levels deviated from the standard of care and is the likely cause of Ms. Lin’s injury. 13 14 Wang Mot., Dkt. 112 at 3–4. 15 Plaintiff does not seek to exclude Dr. Wang’s opinion concerning “Ms. Lin’s current 16 physical status and possible treatment options”. Wang Report, Dkt. 114-3 at 14. 17 a. Opinions 1 and 2 18 Plaintiff argues that the first and second opinions are not helpful to the jury and are 19 not based on sufficient facts. She argues that Dr. Wang lacks sufficient qualifications to 20 offer his third opinion. Defendant argues that Dr. Wang applied a trustworthy 21 methodology to arrive at his first two opinions based on sufficient facts, that the opinions 22 will be helpful to the jury, and that Dr. Wang is qualified to offer his third opinion. 23 Concerning Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Lin v. Solta Medical, Inc., (N.D. Cal. 2024).

Lin v. Solta Medical, Inc. (Lin v. Solta Medical, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Pacific Mutual Life Insurance v. Haslip
499 U.S. 1 (Supreme Court, 1991)
General Electric Co. v. Joiner
522 U.S. 136 (Supreme Court, 1997)
United States v. Roland A. Soulard
730 F.2d 1292 (Ninth Circuit, 1984)
Lisa Stilwell v. Smith & Nephew, Inc., a Corporation
482 F.3d 1187 (Ninth Circuit, 2007)
Avivi v. Centro Medico Urgente Medical Center
71 Cal. Rptr. 3d 707 (California Court of Appeal, 2008)
Voilas v. General Motors Corp.
73 F. Supp. 2d 452 (D. New Jersey, 1999)
Carnegie Mellon University v. Hoffmann-LaRoche, Inc.
55 F. Supp. 2d 1024 (N.D. California, 1999)
Borrayo v. Avery
2 Cal. App. 5th 304 (California Court of Appeal, 2016)
Stephen Wendell v. Glaxosmithkline LLC
858 F.3d 1227 (Ninth Circuit, 2017)
Westberry v. Gislaved Gummi AB
178 F.3d 257 (Fourth Circuit, 1999)
Clausen v. M/V New Carissa
339 F.3d 1049 (Ninth Circuit, 2003)